Progress in Medicinal Chemistry
- 1st Edition, Volume 63 - October 4, 2024
- Editors: Jonathan Bentley, Tilly Bingham
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 2 9 7 8 0 - 9
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 9 7 8 1 - 6
Progress in Medicinal Chemistry, Volume 63 highlights new advances in the field, with this new volume presenting interesting chapters written by an international board of author… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quote- Provides extended, timely reviews of topics in medicinal chemistry
- Contains targets and technologies relevant to the discovery of tomorrow’s drugs
- Presents analyses of successful drug discovery programs
- Progress in Medicinal Chemistry, 63
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Reference
- Chapter One Harnessing conformational drivers in drug design
- Abstract
- Keywords
- 1 Introduction
- 2 Steric clashes
- 2.1 Torsional strain
- 2.2 Impact of substitution on the conformation of the cyclohexane ring
- 2.3 Allylic strain
- 2.4 Syn-pentane
- 3 Lone pair-lone pair repulsion
- 4 Dipole-dipole interaction
- 5 CH-π interaction
- 6 π-π Interaction
- 7 Conjugation
- 7.1 Biaryls
- 8 Intramolecular hydrogen bond (IMHB)
- 9 Gauche effect
- 10 Anomeric effect
- 11 n to σ-hole
- 12 n to π* interaction
- 13 NMR spectroscopy as an invaluable tool in drug design
- 13.1 NMR case studies
- 14 Conclusions
- Acknowledgements
- References
- Chapter Two To homeostasis and beyond! Recent advances in the medicinal chemistry of heterobifunctional derivatives
- Abstract
- Keywords
- Introduction
- 1 Recent advances in the medicinal chemistry of heterobifunctional degraders
- 1.1 First to clinic—The discovery of ARV-110 and ARV-776
- 1.2 Delivering improved DMPK through linkerology—The discovery of CFT8634
- 1.3 Delivering degraders for non-oncology indications—The discovery of the IRAK4 degrader KT-474
- 1.4 Improving physicochemical properties through E3 recruiter warhead modification
- 1.5 Delivering selective target engagement through heterobifunctional degraders
- 2 Recent advances in the screening of heterobifunctional degraders
- 2.1 Approaches to screening degraders
- 2.2 Direct to biology (D2B) approaches
- 3 Extending the repertoire of E3 ligases
- 4 Heterobifunctional degraders beyond E3 ligase recruiters
- 4.1 Degradation via localisation to chaperone proteins (CHAMPs)
- 4.2 Degradation of mitochondria via specific localisation of the ULK1 kinase
- 4.3 Degradation via direct proteasomal recruitment—Targeting RPN11
- 4.4 Inducing protein stability—DUBTACs
- 4.5 Altering post-translational modifications—AceTACs
- 4.6 Deactivation proteins through sequestration—RIPTACs
- 4.7 Selective sub-cellular localisation—TRAMs
- 5 Advances in our understanding of heterobifunctional degrader DMPK
- 5.1 Factors important to achieving good oral exposure
- 5.2 Physicochemical property space
- 5.3 In vivo pharmacokinetic studies
- 5.4 Additional DMPK considerations
- 6 Advances in the scale-up of heterobifunctional degraders for clinical supply—Challenges and solutions
- 7 Heterobunctional bifunctional degraders in the clinic
- Summary and outlook
- Acknowledgements
- References
- Chapter Three Another decade of antimalarial drug discovery: New targets, tools and molecules
- Abstract
- Keywords
- 1 Introduction
- 2 The need for new drug targets; new tools for target validation
- 2.1 Phenotypic vs target-driven approaches
- 2.2 The Malaria Drug Accelerator (MalDA)
- 2.3 Target validation in malaria drug discovery
- 2.4 The NOD scid gamma (NSG) humanized mouse efficacy model
- 2.5 Advances in predictive modelling and the advent of open-source software
- 3 Non-kinase drug targets
- 3.1 ATPase4 (ATP4)
- 3.2 Targeting protein translation in Plasmodium parasites
- 3.3 Acetyl-CoA synthetase (AcAS)
- 3.4 Farnesyl diphosphate synthase/geranylgeranyl diphosphate synthase (FPPS/GGPPS)
- 4 Kinases as targets for malaria
- 4.1 Relevant kinases in current malaria drug discovery
- 4.2 Other Plasmodium kinases and their inhibitors
- 5 Future directions and conclusion
- References
- No. of pages: 260
- Language: English
- Edition: 1
- Volume: 63
- Published: October 4, 2024
- Imprint: Elsevier
- Hardback ISBN: 9780443297809
- eBook ISBN: 9780443297816
JB
Jonathan Bentley
TB
Tilly Bingham
Tilly (Matilda) Bingham is a drug discoverer with over 20 years’ experience of working in the pharmaceutical R&D sector in ‘large pharma’ (Organon, Schering-Plough, MSD), Biotech (Redx Pharma), CRO (Concept Life Sciences) and is currently Executive in Residence at Cumulus Oncology. Tilly’s early career was spent working as a medicinal chemist in CNS therapeutic areas where her research focussed on design strategies for getting small molecule therapeutics across the blood brain barrier for targets including the GPCRs OX2R, V1R and CGRP. Then, as Head of Research and Operations at Redx Pharma she oversaw the discovery and development of oncology and fibrosis clinical candidates, including the clinical candidate porcupine inhibitors RXC004 (oncology), RXC006 (AZD5055, fibrosis), Pan RAF inhibitor (JZP815) and FDA approved BTK inhibitor Pirtobrutinib. As VP Science and Chief Scientific Officer at the UK CRO Concept Life Sciences she oversaw multiple research programmes and the development of new research capability across the group. In her current role as Executive in Residence at Cumulus Oncology Tilly is employing her significant expertise in pre-clinical drug discovery to accelerate oncology innovation to key value inflection points.